A 26-year-old cisgender man with HIV has a new clinic visit to establish care for HIV and start antiretroviral therapy. About 14 months ago, he started receiving long-acting injectable cabotegravir for HIV preexposure prophylaxis (PrEP). He stopped taking the injectable cabotegravir about 4 months ago and did not have any follow-up visits until a recent visit 3 days ago when he tested positive for HIV. The HIV genotypic drug resistance testing (standard resistance assay and integrase resistance assay) is pending. According to the Adult and Adolescent ART Guidelines, which one of the following regimens would be recommended as initial therapy for this patient? Dolutegravir-abacavir-lamivudine Bictegravir-tenofovir alafenamide-emtricitabine Darunavir-cobicistat-tenofovir alafenamide-emtricitabine Atazanavir plus ritonavir plus tenofovir DF-emtricitabine Question Last Updated September 21st, 2023 Steps to Acquire CE for this Question Bank Topic: 1 Answer Questions Answer the board-review style questions 2 Score 80% Answer correctly 3 Claim CE Choose CNE or CME 4 Give Feedback Complete survey 5 Print Certificate Obtain proof of CE
